Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Morphosys Ag ADR (MOR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
MorphoSys and I-Mab Biopharma Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma

PLANEGG/MUNICH GERMANY and SHANGHAI, China / ACCESSWIRE / March 19, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab Biopharma (I-Mab), a China-based clinical...

MOR : 22.94 (-2.09%)
I-Mab Biopharma and MorphoSys Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma

I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, and German biopharma...

MOR : 22.94 (-2.09%)
MorphoSys Presents Results for Fiscal Year 2018

MOR : 22.94 (-2.09%)
NVS : 93.42 (-0.26%)
MorphoSys Provides Updates on L-MIND and B-MIND Clinical Trials of MOR208 in Relapsed/Refractory DLBCL

PLANEGG/ MUNICH, GERMANY / ACCESSWIRE / March 7, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) today provided updates on L-MIND and B-MIND, its two ongoing clinical...

MOR : 22.94 (-2.09%)
Invitation to Year-End Results 2018 Conference Call of MorphoSys AG on March 14, 2019

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX & MDAX; Nasdaq: MOR) will publish its Annual Financial Results 2018 on

MOR : 22.94 (-2.09%)
MorphoSys Announces that its Licensee Janssen Has Received U.S. FDA Approval for Tremfya(R) One-Press Patient-Controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / February 27, 2019 / MorphoSys AG (FSE: MOR) (NASDAQ: MOR) announced today that its licensee Janssen Research & Development, LLC (Janssen), has reported that the...

MOR : 22.94 (-2.09%)
MorphoSys to Present at Upcoming Investor Conference

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / February 21, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) will present at the following conference:

MOR : 22.94 (-2.09%)
Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to Retire

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / February 19, 2019 / Simon Moroney, CEO and co-founder of MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX & MDAX; NASDAQ: MOR), informed the Company's Supervisory...

MOR : 22.94 (-2.09%)
Ad hoc: Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to Retire

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / February 19, 2019 / Simon Moroney, CEO and co-founder of MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX & MDAX; NASDAQ: MOR), informed the Company's Supervisory...

MOR : 22.94 (-2.09%)
MorphoSys Announces Settlement in Patent Lawsuit with Janssen and Genmab

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 31, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that in its lawsuit against Janssen Biotech and Genmab...

MOR : 22.94 (-2.09%)
GNMSF : 177.0000 (+0.60%)
MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Ulcerative Colitis

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 17, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Janssen Research & Development, LLC...

MOR : 22.94 (-2.09%)
MPSYY : 27.9300 (+0.87%)
MPSYF : 90.7500 (-11.42%)
MorphoSys AG: Corporate Calendar 2019

MorphoSys (FSE: MOR; NASDAQ: MOR)

MOR : 22.94 (-2.09%)
MorphoSys's Licensee Janssen Announces Data from the Phase 3 Head-to-Head Study ECLIPSE Demonstrating Superiority of Tremfya(R) vs. Cosentyx(R) as Measured by PASI 90 at Week 48 in the Treatment of Plaque Psoriasis

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 12, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) reported today that its licensee Janssen has announced that results...

MOR : 22.94 (-2.09%)
Griffon Pharmaceuticals appoints Dr. Marc Cluzel to Board of Directors

Montreal-based biopharmaceutical company Griffon Pharmaceuticals Inc. ("Griffon") announced today that Marc Cluzel, MD, PhD, joins the company's Board of Directors.

MOR : 22.94 (-2.09%)
BK Technologies Declares Quarterly Dividend of $0.02 per Share

WEST MELBOURNE, FL / ACCESSWIRE / December 7, 2018 / BK Technologies, Inc. (NYSE: BKTI) today announced that today its Board of Directors declared a quarterly dividend of $0.02 per share of the Company's...

IIPR : 87.75 (-2.59%)
AAPL : 191.05 (-2.07%)
TX : 26.97 (-4.09%)
EFR.TO : 4.25 (-1.62%)
CIIX : 0.4700 (-1.05%)
ITRO : 0.8960 (+2.02%)
CNDGF : 0.2906 (-9.19%)
ZC.VN : 0.260 (+4.00%)
PKTEF : 0.2700 (+1.89%)
CRON : 19.23 (-6.38%)
VFC : 83.72 (-2.47%)
ACBFF : 8.6900 (-12.80%)
CVSI : 5.7100 (+5.16%)
COUP : 90.40 (-8.95%)
Y.TO : 5.90 (unch)
GRUB : 68.59 (-1.66%)
MDR : 7.03 (-5.64%)
ESK.VN : 0.140 (-15.15%)
EA : 102.34 (-2.42%)
CLSK : 3.4700 (-1.42%)
BABA : 176.26 (-2.89%)
MO : 55.92 (-1.77%)
XXMMF : 0.4530 (+1.68%)
AEM : 44.29 (-0.20%)
SING : 0.0159 (-6.47%)
EW : 188.99 (-1.64%)
DATA : 127.85 (-6.43%)
EIX : 64.69 (-0.45%)
XIM.VN : 0.580 (unch)
ATVI : 46.87 (-3.56%)
HTHT : 39.00 (-1.84%)
SSRM : 13.06 (+1.79%)
JRSH : 7.15 (-0.69%)
ZTMUF : 0.1756 (-2.17%)
MAR : 124.50 (-0.45%)
EXE.TO : 7.57 (+0.40%)
GBT.TO : 15.17 (+0.46%)
NBEV : 5.08 (-5.05%)
AVGO : 292.65 (-1.40%)
ORRP : 0.2456 (+6.78%)
DIIBF : 9.2100 (-2.69%)
FDIT : 0.0390 (+5.41%)
CMCM : 6.77 (-3.56%)
KLGDF : 10.5858 (+1.11%)
SHOP : 198.75 (-3.05%)
ESKYF : 0.1014 (+71.57%)
APOG : 35.22 (-2.57%)
SIA.TO : 18.47 (-0.27%)
TSRO : 74.96 (+0.03%)
GE : 9.98 (-2.82%)
NKTR : 32.17 (-3.91%)
ACB : 9.03 (-5.64%)
TWLO : 129.53 (-4.52%)
BKTI : 4.30 (+2.38%)
GLUU : 10.70 (-1.56%)
KR : 24.34 (+0.08%)
MGI : 2.14 (-4.89%)
MKL : 984.51 (-0.59%)
MOR : 22.94 (-2.09%)
OCLN : 0.0011 (unch)
IDTI : 47.79 (-0.10%)
AMRN : 17.51 (-6.66%)
APHA : 9.53 (-5.27%)
APTI : 37.97 (-0.03%)
L.TO : 65.63 (-0.15%)
MorphoSys Presents Updated Data from L-MIND Study of MOR208 plus Lenalidomide in r/r DLBCL at ASH 2018

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 1, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) today presented data from the ongoing single-arm phase 2 clinical trial...

MOR : 22.94 (-2.09%)
MorphoSys Announces Approval of Tremfya(R) (Guselkumab) in Japan for the Treatment of Patients with Palmoplantar Pustulosis

PLANEGG/MUNICH, GERMANY, / ACCESSWIRE / November 26, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee's affiliate, Janssen Pharmaceutical...

MOR : 22.94 (-2.09%)
InflaRx N.V. Reports Third Quarter 2018 Financial & Operating Results

-- First patient dosed in phase II trial with IFX-1 in ANCA-associated vasculitis

MOR : 22.94 (-2.09%)
IFRX : 43.69 (-3.66%)
MorphoSys to Present at Upcoming Investor Conferences

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / November 21, 2018 / MorphoSys to Present at Upcoming Investor Conferences

MOR : 22.94 (-2.09%)
MorphoSys Announces Its Licensee Janssen Initiated a Phase 2 Study (NOVA) to Evaluate Guselkumab in Hidradenitis Suppurativa

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 19, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Janssen Research & Development,...

MOR : 22.94 (-2.09%)

Van Meerten Stock Picks

Trilogy Metals - Pick of the Day
My Stock Pick of the Day belongs metal mining company Trilogy Metals(TMQ).
TMQ -0.16
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar